Key issues concerning fungistatic versus fungicidal drugs

被引:47
作者
Graybill, JR
Burgess, DS
Hardin, TC
机构
[1] UNIV TEXAS, HLTH SCI CTR, DEPT PHARMACOL, SAN ANTONIO, TX 78284 USA
[2] AUDIE L MURPHY MEM VET ADM MED CTR, MED SERV, INFECT DIS SECT, SAN ANTONIO, TX 78284 USA
[3] UNIV TEXAS, COLL PHARM, AUSTIN, TX 78712 USA
关键词
D O I
10.1007/BF01575120
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Are there any fungicidal drugs available today? A critical issue in answering this question is that of definition. The simplest, most stringent definitions identify fungistatic drugs as those that inhibit growth, whereas fungicidal drugs kill fungal pathogens. The immunocompetent host is usually far better equipped to eliminate fungal pathogens than the immunosuppressed host. Therefore, it would be especially desirable to have a truly fungicidal drug, one that absolutely kills all fungi, as a treatment option for the immunosuppressed patient. The critical question would be whether a fungicidal drug can be delivered to the target site in a concentration high enough for a sufficient time to reduce the intralesional fungal counts to zero. By this simple definition, there are no fungicidal drugs available today. However, an accepted alternative definition is that often used by the bacteriologist: Fungicidal drugs are those that lead to a reduction of 99.9% of the initial inocula. Although this less restrictive in vitro standard is more easily met, it has serious limitations. Whether the 99.9% kill should be an acceptable standard remains uncertain. As an alternative, the minimum inhibitory concentration, though indicating static activity, has served well; perhaps it should be the only information reported for fungal susceptibility testing.
引用
收藏
页码:42 / 50
页数:9
相关论文
共 61 条
  • [11] AMPHOTERICIN-B INDUCES TUMOR NECROSIS FACTOR PRODUCTION BY MURINE MACROPHAGES
    CHIA, JKS
    POLLACK, M
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1989, 159 (01) : 113 - 116
  • [12] PHARMACOLOGICAL MODULATION OF INTERLEUKIN-1 EXPRESSION BY AMPHOTERICIN B-STIMULATED HUMAN MONONUCLEAR-CELLS
    CLEARY, JD
    CHAPMAN, SW
    NOLAN, RL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (05) : 977 - 981
  • [13] CYTOKINE TREATMENT OF CENTRAL-NERVOUS-SYSTEM INFECTION - EFFICACY OF INTERLEUKIN-12 ALONE AND SYNERGY WITH CONVENTIONAL ANTIFUNGAL THERAPY IN EXPERIMENTAL CRYPTOCOCCOSIS
    CLEMONS, KV
    BRUMMER, E
    STEVENS, DA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (03) : 460 - 464
  • [14] DISCREPANCIES BETWEEN MIC AND MLC VALUES OF AMPHOTERICIN-B AGAINST ISOLATES OF ASPERGILLUS SPECIES
    COLOMBO, AL
    MCGOUGH, DA
    RINALDI, MG
    [J]. MYCOPATHOLOGIA, 1994, 128 (03) : 129 - 133
  • [15] COMO JA, 1994, NEW ENGL J MED, V330, P263, DOI 10.1056/NEJM199401273300407
  • [16] AMPHOTERICIN-B AS PRIMARY THERAPY FOR CRYPTOCOCCOSIS IN PATIENTS WITH AIDS - RELIABILITY OF RELATIVELY HIGH-DOSES ADMINISTERED OVER A RELATIVELY SHORT-PERIOD
    DELALLA, F
    PELLIZZER, G
    VAGLIA, A
    MANFRIN, V
    FRANZETTI, M
    FABRIS, P
    STECCA, C
    [J]. CLINICAL INFECTIOUS DISEASES, 1995, 20 (02) : 263 - 266
  • [17] Is it ever safe to stop azole therapy for Coccidioides immitis meningitis?
    Dewsnup, DH
    Galgiani, JN
    Graybill, JR
    Diaz, M
    Rendon, A
    Cloud, GA
    Stevens, DA
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 124 (03) : 305 - +
  • [18] TREATMENT OF CRYPTOCOCCAL MENINGITIS WITH COMBINATION AMPHOTERICIN-B AND FLUCYTOSINE FOR 4 AS COMPARED WITH 6 WEEKS
    DISMUKES, WE
    CLOUD, G
    GALLIS, HA
    KERKERING, TM
    MEDOFF, G
    CRAVEN, PC
    KAPLOWITZ, LG
    FISHER, JF
    GREGG, CR
    BOWLES, CA
    SHADOMY, S
    STAMM, AM
    DIASIO, RB
    KAUFMAN, L
    SOONG, SJ
    BLACKWELDER, WC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (06) : 334 - 341
  • [19] A CONTROLLED-STUDY OF RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN ELDERLY PATIENTS AFTER TREATMENT FOR ACUTE MYELOGENOUS LEUKEMIA
    DOMBRET, H
    CHASTANG, C
    FENAUX, P
    REIFFERS, J
    BORDESSOULE, D
    BOUABDALLAH, R
    MANDELLI, F
    FERRANT, A
    AUZANNEAU, G
    TILLY, H
    YVER, A
    DEGOS, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (25) : 1678 - 1683
  • [20] AMPHOTERICIN-B IN THE TREATMENT OF COCCIDIOIDOMYCOSIS
    DRUTZ, DJ
    [J]. DRUGS, 1983, 26 (04) : 337 - 346